加载中
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
收盘时
US$122.4
−US$8.50 · -6.49%
盘后
US$123.94
+US$1.54 · +1.26%
10月12日 17:46 ET
盘中时间采用ET。市场数据可能有所延迟。
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
日内区间
当前US$122.4
52周区间
当前US$122.4
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
40
偏贵
情绪
58
多空交织
风险
41
风险偏高
动量
70
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
日内区间
当前US$122.4
52周区间
当前US$122.4
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 |
|---|---|---|---|
| 研究与开发 | 6206.5万 USD | 2328.3万 USD | 1497.1万 USD |
| 销售、一般及管理费用 | 1028.2万 USD | 349.5万 USD | 235.3万 USD |
| 营业费用 | 7234.7万 USD | 2677.8万 USD | 1732.4万 USD |
| 利息收入 | 156.2万 USD | 48.1万 USD | 87万 USD |
| 利息支出 | — | 58.5万 USD | 3.6万 USD |
| 营业利润 | −7234.7万 USD | −2677.8万 USD | −1732.4万 USD |
| 净利润 | −6999.5万 USD | −2648.8万 USD | −1649万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$162.67
上涨空间 32.90%评级样本有限，仅4项
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
